Our Research

As a leader in IBD care, CCCure is committed to progressing research that provides insights into care optimisation, and providing high quality data to drive improved outcomes. Our innovative CCCare platform plays a pivotal role in supporting research, developing innovative treatments, and working toward finding a cure for IBD.

Visit our CCCare page to learn more about it and how it can benefit individuals and organisations.

Peer-Reviewed Publications

BLANK

Accordion Content

Proposal and exploration of a novel score to quantify patient-perceived burden of inflammatory bowel disease under routine care (January 2025)

Joseph L Pipicella, Bonita Gu, Jack McNamara, William Wilson, Lyle J Palmer, Susan J Connor, Jane M Andrews

Read article in Internal Medicine Journal

Benchmarking in inflammatory bowel disease: lessons from Australia and New Zealand (January 2025)

Peter Litwin & Jane M Andrews

Read article in Journal of the Canadian Association of Gastroenterology

Epidemiology and Treatment Patterns of Fistulizing Crohn’s Disease in a Large, Real-World Australasian Cohort (November 2024)

Jack McNamara, William Wilson, Joseph L Pipicella, Simon Ghaly, Jakob Begun, Ian C Lawrance, Richard Gearry, Jane M Andrews, Susan J Connor

Read article in Gastro Hep Advances

Co-design of an eHealth clinical management system for children with inflammatory bowel disease: consensus amongst people with inflammatory bowel disease, parents and clinicians (October 2023)

Joseph L Pipicella, Angharad Vernon‑Roberts, Shoma Dutt, Edward Giles, Andrew S Day, Susan J Connor, Jane M Andrews

“…widespread consumer co-design and consultation ensure vital functionality is not missed, resulting in a product meeting the needs of all consumers.”

Read article in Digestive Diseases and Sciences

The Evolving Role of Technology in Delivering Patientcentric, Empowered Health Care in Inflammatory Bowel Disease: Patient Experience Using Crohn’s Colitis Care e-Health Consumer Platform (July 2023)

Jack McNamara, Susan J Connor, Jane M Andrews

“This highlights the importance of technology in facilitating communication and willingness of patient consumers to use technology as part of their health care delivery when invited to do so.”

Read article in Inflammatory Bowel Diseases

Integration of mental health and quality of life screening tools in an IBD-specific electronic medical record (Crohn Colitis Care): process and early outcomes (January 2023)

Taryn Lores, Krupa Krishnaprasad, Susan J Connor, Aura Cabaero, Jane M Andrews

“Integrating brief screening questionnaires into clinical management software enables proactive screening for psychological distress and impaired QoL in people with IBD.”

Read article in Internal Medicine Journal

Novel IBD specific electronic medical record allows scalable auditing of IBD severity, therapy and complications to show the current unmet need in IBD care (April 2022)

Alex Barnes, David Carter, Patricia Kaazan, Alissa Walsh, Susan J Connor, Jane M Andrews

“CCCare can be used to examine concordance between patients’ and doctors’ judgements of disease activity. CCCare will also enable quality data on extraintestinal manifestations to be reported for incidence and prevalence and better inform their relationship to disease activity and response to various therapies in large cohorts.”

Read artical in Intestinal Research

Assessing effectiveness and patient perceptions of a novel electronic medical record for the management of IBD (August 2021)

Patricia Kaazan, Tracy Li, Warren Seow, Jana Bednarz, Joseph L Pipicella, Krupa Krishnaprasad, Watson Ng, Astrid-Jane Williams, Susan J Connor, Jane M Andrews

“CCCare is effective in supporting more complete IBD-specific data capture compared with usual medical records. It is highly acceptable to patients, especially those with reasonable IT literacy. Patient concerns about privacy and security of electronic medical records (EMRs) did not significantly affect acceptability.”

Read article in Journal of Gastroenterology and Hepatology

Crohn’s Colitis Care (CCCare): bespoke cloud-based clinical management software for inflammatory bowel disease (November 2020)

Krupa Krishnaprasad, Alissa Walsh, Jakob Begun, Sally Bell, David Carter, Rachel Graftonh, Alexandra Sechi, Karen Sewell, Anna McMahon, Susan J Connor, Graham Radford-Smith, Jane M Andrews

“Initial evaluation demonstrates CCCare is usable, secure, and valued in clinical use. It is designed to measure outcomes of clinical care, including efficacy, quality, cost, and complications for individuals, and to audit these at hospital and national level.”

Read article in Scandinavian Journal of Gastroenterology

Upcoming Manuscripts

BLANK

Accordion Content

Burden of disease in IBD in Australasia 2022: A Regional Cross Section Burden of Disease Report

Contact [email protected] for more information.

A Retrospective Study on Steroid Burden in Australia

Contact [email protected] for more information.

Quality, safety and equity of care outcomes for inflammatory bowel disease patients at four Australia tertiary referral centres: a real-world observational study

McNamara et al.

Contact [email protected] for more information.

Outcomes for people with Inflammatory Bowel Disease receiving dose escalated Adalimumab Therapy – Crohn’s Colitis Cure (CCC) Data Insight’s Program

McGrory et al.

Contact [email protected] for more information.

Accepted Abstracts

2025

FEBRUARY 2025
20th Congress of European Crohn's and Colitis Organisation (ECCO) - Berlin, Germany

BLANK

Accordion Content

Inflammatory Bowel Disease nursing helpline trends in a large real-world Australasian cohort: Crohn's Colitis Cure (CCC) data insights program

Chan P, Su WK, Wilson W, Cabaero A, Antoniades S, Forbes A, Anormal K, Grafton R, Andrews J, Connor S

Comparing real-world use of Dietary and Medical Therapies in Children & Adults with IBD

Barnett M, Su WK, Pipicella J, Kaur H, Wilson W, Connor SJ, Andrews JM

A cross-sectional study of Older Person's IBD across Australasia, Crohn's Colitis Cure Data Insights Program

Seng C, Su WK, Wilson W, Connor SJ, Andrews JM, Walker G

The real-world use of intravenous and subcutaneous Vedolizumab in IBD across Australia and New Zealand, Crohn's Colitis cure Data Insight's Program

WK Su, W Wilson, G Wark, S Ghaly, K Lynch, I Lawrance, G Walker, A Forbes, L Brett, YK An, SJ Connor, JM Andrews

Consistency and Quality of Inflammatory Bowel Disease care in Australasia; towards benchmarking, Crohn's Colitis Cure Data Insight's Program

Wai Kin Su

Variation in healthcare utilisation amongst IBD care centres in Australia and New Zealand, Crohn's Colitis Care Data Insight's Program

WK Su, W Wilson, G Wark, G Walker, H Su, A Forbes, A Kim, E Giles, I Lawrance, S Dutt, L Brett, J Begun, K Lynch, JM Andrews, SJ Connor

Geographic disparities in Healthcare Utilisation in people with Inflammatory Bowel Disease, Crohn's Colitis Cure Data Insights Program

Wai Kin Su

Corticosteroid and opiate use in inflammatory bowel disease, 25 years after the TREAT registry was established

Pinnuck B, Su W, Wilson W, Pipicella J, Wark G, Arcidiacono M, Walker G, Forbes A, Su H, Schultz M, Lawrence I, Dutt S, Brett L, Connor S, Lynch K & Andrews JM.

Iron deficiency, with or without anaemia, in inflammatory bowel disease remains an undermanaged issue: Crohn's Colitis Cure Data Insights Program

Pinnuck B, Su W, Wilson W, Pipicella J, Ng W, Antoniades S, Walker G, Forbes A, Dutt S, Lynch K, Connor S & Andrews JM.

Patterns and predictors of steroid use in people with IBD in routine care across ANZ

Rivas C, Su W, Wilson W, Ng W, Ghaly S, Walker G, Forbes A, Su H, Schultz M, Lawrence I, Dutt S, Brett L, Begun J, Lynch K, Andrews JM, Connor S.

Factors associated with inflammatoy bowel disease (IBD) helpline (HL) utilisation: Crohn's Colitis Cure Data Insight's Program

Davidson C, Su W, Wilson W, Rivas C, Antoniades S, Wark G, Su H, Ghaly S, Grafton R, Andrews JM, Connor SJ

Inflammatory bowel disease helpline use amongst the culturally and linguistically diverse population, Crohn's Colitis Cure Data Insight's Program

AG Cabaero, WK Su, W Wilson, C Rivas, S Antoniades, W Ng, A Forbes, K Arnold, R Grafton, JM Andrews, SJ Connor

Mortality and comorbidities in people with inflammatory bowel disease - Crohn's Colitis Cure Data Insight's program

Alsulaibi O, Su W, Wilson W, Sin L, Ng W, Walker G, Forbes A, Lawrance I, Lynch K, Begun J, Connor SJ, Andrews JM

Active perianal fistulising Crohn's Disease is associated with a higher burden of psychological distress, depression, anxiety, stress and opioid use

Gu B, Su WK, Nano D, Wilson B, Iliescu S, Lynch K, Andrews JM, Connor SJ, Ghaly S

2024

FEBRUARY 2024
19th Congress of European Crohn's and Colitis Organisation (ECCO) - Stockholm, Sweden

BLANK

Accordion Content

Fistulising Crohn's Disease in a large Australasian cohort - Crohn's Colitis Cure (CCC) Data Insights Program

McNamara et al.

Journal of Crohn’s and Colitis

19th Congress of ECCO

Available here

View Poster

The burden of mental health disease in people with inflammatory bowel disease - Crohn's Colitis Cure (CCC) Data Insights Program

McNamara et al.

Journal of Crohn’s and Colitis

19th Congress of ECCO

Available here

View Poster

Variation of outcomes in inflammatory bowel disease at ten Australasian centres - Crohn's Colitis Cure (CCC) Data Insights Program

McNamara et al.

Journal of Crohn’s and Colitis

19th Congress of ECCO

Available here

View Poster

Dose escalated Ustekinumab in Inflammatory Bowel Disease - Crohn's Colitis Cure (CCC) Data Insights Program

Barnett et al.

Journal of Crohn’s and Colitis

19th Congress of ECCO

Available here

View Poster

Dose escalated vedolizumab in Inflammatory Bowel Disease - Crohn's Colitis Cure (CCC) Data Insights Program

McNamara et al.

Journal of Crohn’s and Colitis

19th Congress of ECCO

Available here

View Poster

Dose escalated Infliximab in Inflammatory Bowel Disease - Crohn's Colitis Cure (CCC) Data Insights Program

Alshiwanna et al.

Journal of Crohn’s and Colitis

19th Congress of ECCO

Available here

View Poster

Inflammatory Bowel Disease helpline contact trends in a real-world Australasian cohort: Crohn’s Colitis Cure (CCC) data insight’s program

Pipicella et al.

Journal of Crohn’s and Colitis

19th Congress of ECCO

Available here

View Poster

Assessing patient-perceived burden of disease in Crohn’s disease: a novel scoring approach in a real-world Australasian cohort

Pipicella et al.

Journal of Crohn’s and Colitis

19th Congress of ECCO

Available here

View Poster

Assessing patient-perceived burden of disease in Ulcerative Colitis: a novel scoring approach in a real-world Australasian cohort

Gu et al.

Journal of Crohn’s and Colitis

19th Congress of ECCO

Available here

View Poster

The real-world use of five-aminosalicylate (5ASA) treatment for Ulcerative Colitis in Australia and New Zealand: Crohn’s Colitis Cure (CCC) data insight’s program

Pipicella et al.

Journal of Crohn’s and Colitis

19th Congress of ECCO

Available here

View Poster

A glance into paediatric Inflammatory Bowel Disease in Australasia – Crohn’s Colitis Cure (CCC) data insights program

Pipicella et al.

Journal of Crohn’s and Colitis

19th Congress of ECCO

Available here

View Poster

MAY 2024
Digestive Disease Week (DDW) - Washington, USA

BLANK

Accordion Content

The Burden of Mental Health Disease in People with Inflammatory Bowel Disease - Crohn's Colitis Cure (CCC) Data Insights Program

J McNamara, W Wilson, JL Pipicella, S Ghaly, R Gearry, A Williams, K Lynch, I Lawrance, M Schultz, G Walker, G Radford-Smith, SJ Connor, JM Andrews

Gastroenterology

Digestive Diseases Week (DDW) 2024

Available here

View Poster

Assessing Patient-Perceived Burden Of Disease In Ulcerative colitis: A Novel Scoring Approach In A Real-World Australasian Cohort

B. Gu, J.L. Pipicella, L. Palmer, S.J. Connor, W. Wilson, J.M. Andrews

Gastroenterology

Digestive Diseases Week (DDW) 2024

Available here

View Poster

Assessing Patient-Perceived Burden Of Disease In Crohn’s Disease: A Novel Scoring Approach In A Real-World Australasian Cohort

J.L. Pipicella, B. Gu, L. Palmer, S.J. Connor, W. Wilson, J.M. Andrews.

Gastroenterology

Digestive Diseases Week (DDW) 2024

Available here

View Poster

Real-World Use of Five-Aminosalicylate (5ASA) Treatment for Ulcerative Colitis in Australia & New Zealand: Crohn’s Colitis Cure (CCC) Data Insight’s Program

J.L. Pipicella, J. McNamara, W. Wilson, K. Lynch, G. Walker, J. Begun, I. Lawrance, S. Ghaly, G. Radford-Smith, A.J. Williams, R. Gearry, M. Schultz, L. Brett, J.M. Andrews, S.J. Connor.

Gastroenterology

Digestive Diseases Week (DDW) 2024

Available here

View Poster

Dose escalated vedolizumab in Inflammatory Bowel Disease –Crohn’s Colitis Cure (CCC) Data Insights Program

J. McNamara, B. Alshiwanna, W. Wilson, J.L. Pipicella, S. Ghaly, R. Gearry, J. Begun, W. Ng, K. Lynch, I. Lawrance, M. Schultz, G. Walker, G. Radford-Smith, J.M. Andrews, S.J. Connor

Gastroenterology

Digestive Diseases Week (DDW) 2024

Available here

View Poster

Dose escalated Ustekinumab in Inflammatory Bowel Disease - Crohn's Colitis Cure (CCC) Data Insights Program

M. Barnett, J. McNamara, W. Wilson, J.L. Pipicella, S. Ghaly, R. Gearry, J. Begun, A.J. Williams, K. Lynch, I. Lawrance, M. Schultz, G. Walker, G. Radford-Smith, S.J. Connor, J.M. Andrews

Gastroenterology

Digestive Diseases Week (DDW) 2024

Available here

View Poster

Dose escalated Infliximab in Inflammatory Bowel Disease - Crohn's Colitis Cure (CCC) Data Insights Program

B. Alshiwanna, J. McNamara, W. Wilson, J.L. Pipicella, S. Ghaly, R. Gearry, J. Begun, A.J. Williams, K. Lynch, I. Lawrance, M. Schultz, G. Walker, G. Radford-Smith, S.J. Connor, J.M. Andrews

Gastroenterology

Digestive Diseases Week (DDW) 2024

Available here

View Poster

Variation in Outcomes in Inflammatory Bowel Disease at 10 Australasian Centres - Crohn's Colitis Cure (CCC) Data Insights Program

J. McNamara, S. Ghaly, J.L. Pipicella, W. Wilson, T. Goodfellow, M. Cheema, K. Lynch, A. Williams, J. Begun, R. Gearry, A. Kim, C. Haifer, A. Forbes, I. Lawrance, M. Schultz, G. Walker, G. Radford-Smith, J.M. Andrews, S.J. Connor

Gastroenterology

Digestive Diseases Week (DDW) 2024

Available here

View Poster

SEPTEMBER 2024
Australian Gastroenterology Week (AGW) - Adelaide, Australia

BLANK

Accordion Content

The real-world use of five aminosalicylate treatment for ulcerative colitis – Crohn’s Colitis Cure Data Insight’s Program

Su W, Wilson W, Pipicella J, Haifer C, Lynch K, Forbes A, Walker G, Schultz M, Lawrance I, An Y, Brett L, Connor S, Andrews J

Journal of Gastroenterology and Hepatology

Australian Gastroenterology Week (AGW) 2024

Available here

View Poster

Healthcare Utilisation in people with inflammatory bowel disease – Crohn’s Colitis Cure (CCC) Data Insights Program

Su W, Pipicella J, Wilson W, Kim A, Davison C, Giles E, Walker G, Forbes A, Su H, Lawrance I, Dutt S, Lynch K, Brett L, Begun J, Connor S, Andrews J

Journal of Gastroenterology and Hepatology

Australian Gastroenterology Week (AGW) 2024

Available here

The burden of mental health issues in people with inflammatory bowel disease in Australasia: Crohn’s Colitis Cure (CCC) data insights program

T Lores, S Iliescu, W Su, W Wilson, K Leray, G Kuzet, K Lynch, J Andrews, SJ Connor

Journal of Gastroenterology and Hepatology

Australian Gastroenterology Week (AGW) 2024

Available here

View Poster

A cross section of inflammatory bowel disease management in older persons in Australasia: Crohn’s Colitis Cure (CCC) data insights program

Seng C, Su W, Wilson W, Haifer C, Williams AJ, Forbes A, Lawrance I, Lynch K, Brett L, Begun J, Connor SJ, Andrews J, Walker G

Journal of Gastroenterology and Hepatology

Australian Gastroenterology Week (AGW) 2024

Available here

View Poster

Inflammatory bowel disease nurse helpline contact trends in a large real-world Australasian cohort: Crohn’s Colitis Cure (CCC) data insights programTitle

Su W, Chan P, Pipicella J, Wilson W, Antoniades S, Cabaero G, Forbes A, Arnold K, Grafton R, Andrews J & Connor S

Journal of Gastroenterology and Hepatology

Australian Gastroenterology Week (AGW) 2024

Available here

View Poster

Comparing Real-World Use of Dietary & Medical Therapies in Children & Adults with IBD: A Cross-Sectional Study Using Data from the Crohn’s Colitis Care (CCCare) Clinical Quality Registry

JL Pipicella, WK Su, W Wilson, JM Andrews, SJ Connor

Journal of Gastroenterology and Hepatology

Australian Gastroenterology Week (AGW) 2024

Available here

Oral Presentation

The prevalence and impact of obesity in an ANZ cohort of people with inflammatory bowel disease: Crohn’s Colitis Cure (CCC) data insights program

Kaazan, P, Su W, Wilson W, Dinoy E, Wark G, Walker G. Forbes A, Schultz M, Yap J, Rayner CK, Lawrence I, Dutt S, Lynch K, Brett L, Begun J, Andrews JM, Connor SJ

Journal of Gastroenterology and Hepatology

Australian Gastroenterology Week (AGW) 2024

Available here

View Poster

Dose escalated therapy improving outcomes in inflammatory bowel disease – Crohn’s Colitis Cure (CCC) Data Insights Program

Su W, Wilson W, Ng W, Whittaker C, Giles E, Walker G, Forbes A, Lawrance I, Dutt S, Lynch K, Brett L, An Y, Connor S, Andrews J

Journal of Gastroenterology and Hepatology

Australian Gastroenterology Week (AGW) 2024

Available here

View Poster

The psycho-social impact of fistulising perianal Crohn’s disease in Australasia: Crohn’s Colitis Cure (CCC) data insights program

Dominique Nano, Wai Kin Su, Jack McNamara, William Wilson, Arteen Arzivian, Astrid-Jane Williams, Gareth Walker, Angela Forbes, Heidi Su, Edward Giles, Ian Lawrance, Shoma Dutt, Kate Lynch, Laurel Brett, Jakob Begun, Jane Andrews, and Susan J Connor

Journal of Gastroenterology and Hepatology

Australian Gastroenterology Week (AGW) 2024

Available here

Oral Presentation

Iron deficiency with or without anaemia continues to be an issue in inflammatory bowel disease – Crohn’s Colitis Cure (CCC) data insight’s program

Pinnuck B, Su W, Wilson W, Pipicella J, Ng W, Antoniades S, Walker G, Forbes A, Dutt S, Lynch K, Connor S & Andrews J.

Journal of Gastroenterology and Hepatology

Australian Gastroenterology Week (AGW) 2024

Available here

View Poster

Documented variation in inflammatory bowel disease care in Australasia – Crohn’s Colitis Cure (CCC) Data Insights Program

Su W, McNamara J, Pipicella J, Wilson W, Ghaly S, Cabaero A, Walker G, Forbes A, Su H, Brett L, Dutt S, An Y, Lawrance I, Lynch K, Andrews J, Connor S

Journal of Gastroenterology and Hepatology

Australian Gastroenterology Week (AGW) 2024

Available here

View Poster

Mortality in Inflammatory Bowel Disease – Crohn’s Colitis Cure (CCC) Data Insights Program

Alsulaibi O, Su W, Wilson W, Sin L, Ng W, Walker G, Forbes A, Lawrance I, Lynch K, Begun J, Connor SJ, Andrews JM

Journal of Gastroenterology and Hepatology

Australian Gastroenterology Week (AGW) 2024

Available here

View Poster

Exploring a novel score to assess the Patient Perceived Burden of Disease in Crohn’s Disease and Ulcerative Colitis – Crohn’s Colitis Cure (CCC) Data Insights Program

Su W, Gu B, Pipicella J, Wilson W, Kim A, Wark G, Giles E, Walker G, Forbes A, Su H, Dutt S, An Y, Lawrance I, Lynch K, Connor S, Andrews J

Journal of Gastroenterology and Hepatology

Australian Gastroenterology Week (AGW) 2024

Available here

View Poster

Corticosteroid and opiate use in inflammatory bowel disease, 25 years after the TREAT Registry was established

Pinnuck B, Su W, Wilson W, Pipicella J, Wark G, Arcidiacono M, Walker G, Forbes A, Su H, Schultz M, Lawrence I, Dutt S, Brett L, Lynch K, Andrews J & Connor S.

Journal of Gastroenterology and Hepatology

Australian Gastroenterology Week (AGW) 2024

Available here

View Poster

2023

BLANK

Accordion Content

Quality, safety and equity of care outcomes for inflammatory bowel disease patients at four tertiary referral centres in Australia using a cloud based management system Crohn’s Colitis Care (CCCare): A real world observational study.

Cheema et al.

Journal of Crohn’s and Colitis

18th Congress of ECCO

Available here

Real World, National Experience of Escalated Dosing Of Adalimumab in People With Inflammatory Bowel Disease

McGrory et al.

Gastroenterology (2023)

Digestive Diseases Week 2023

Available here

Quality, Safety And Equity Of Care Outcomes For Inflammatory Bowel Disease Patients At Four Australian Tertiary Referral Centres Using The Cloud-Based Management System Crohn's Colitis Care (CCCare): A Real World Observational Study

Cheema et al.

Gastroenterology (2023)

Digestive Diseases Week 2023

Available here

Disease and treatment factors influencing outcomes in fistulising Crohn’s Disease

McNamara et al.

Gut (2023)

International Digestive Disease Forum 2023

Available here

The evolving role of technology in delivering patient-centric care in inflammatory bowel disease – an Australasian experience using Crohn’s Colitis Care E-health patient portal

McNamara et al.

Gut. (2023)

International Digestive Disease Forum 2023

Available here

Variation in Outcomes in Inflammatory Bowel Disease at ten Australian and New Zealand centres – Crohn’s Colitis Cure (CCC) Data Insights Program

McNamara et al.

J Gastroenterol Hepatol. (2023)

Australian Gastroenterology Week 2023

Available here

Outcomes for people with inflammatory bowel disease receiving dose-escalated adalimumab therapy: Crohn's Colitis Cure data insights program

McGrory et al.

J Gastroenterol Hepatol. (2023)

Australian Gastroenterology Week 2023

Available here

The Burden of Disease in Inflammatory Bowel Disease in Australasia – Crohn’s Colitis Cure (CCC) Data Insights Program

McNamara et al.

J Gastroenterol Hepatol. (2023)

Australian Gastroenterology Week 2023

Available here

The Burden of Mental Health Issues in people with Inflammatory Bowel Disease in Australasia

McNamara et al.

J Gastroenterol Hepatol. (2023)

Australian Gastroenterology Week 2023

Available here

The Evolving role of technology in delivering consumer centric care in Inflammatory Bowel Disease - an Australasian experience with Crohn’s Colitis Care’s E-health consumer portal

McNamara et al.

J Gastroenterol Hepatol. (2023)

Australian Gastroenterology Week 2023

Available here

Fistulising Crohn’s Disease in a large real-world cohort – Crohn’s Colitis Cure (CCC) Data Insights Program

McNamara et al.

J Gastroenterol Hepatol. (2023)

Australian Gastroenterology Week 2023

Available here

2022

BLANK

Accordion Content

Designing an eHealth clinical management system for young people with IBD: Consensus opinion on topics for inclusion by patients, parents and clinicians.

Pipicella et al.

Journal of Gastroenterology and Hepatology 37 (Suppl. 1) (2022) pp. 224

Australian Gastroenterology Week 2022

Available here

What do young people with inflammatory bowel disease, their parents/carers and clinicians value for inclusion in a disease-specific electronic medical record?

Pipicella et al.

Pediatric Gastroenterology, Hepatology & Nutrition 3 (Suppl. 1) (2022) pp. 145-146

6th International Symposium on Paediatric Inflammatory Bowel Disease 2022

Available here

Inflammatory Bowel Disease In Canterbury, New Zealand – Descriptive epidemiology Using Crohn’s Colitis Care

Forbes et al.

Gastroenterology and Hepatology From Bed to Bench 16 (Suppl. 1) (2023) pp. S28-S29

New Zealand Society of Gastroenterology Annual Scientific Meeting 2022

Available here

2021

BLANK

Accordion Content

Novel inflammatory bowel disease-specific electronic medical record allows scalable auditing of disease severity, therapy, complications, and the unmet need in care

Barnes et al.

Journal of Gastroenterology and Hepatology

Australian Gastroenterology Week 2021

Available here

Using a Consensus-Based Method to Develop a Novel Paediatric-Specific IBD eHealth Clinical Management System

Pipicella et al.

Journal of Gastroenterology and Hepatology

Australian Gastroenterology Week 2021

Available here

Using a Consensus-Based Method to Develop a Novel Paediatric-Specific IBD eHealth Clinical Management System

Pipicella et al.

Gut 70 (Suppl 2) (2021) pp. A109-A109

International Digestive Disease Forum 2021

Available here

Assessing effectiveness and patient perceptions of a novel EMR for the management of IBD

Kaazan et al.

Journal of Gastroenterology and Hepatology

Australian Gastroenterology Week 2020

Available here

Conflict of Interest (COI) Declarations

Owen Alsulaibi

COI Declaration for ECCO 2025: None

Jane M Andrews

COI Declaration for ECCO 2025: Speaker‘s fees, research support, Ad Boards, industry consultation within last 3 years: Abbvie, BMS, Celgene, Celltrion, Falk, Ferring, Fresenius Kabi, Gilead, Janssen, J&J, MSD/Organon, Nestle, Novartis, Pfizer, Sandoz, Shire, Takeda, Vifor, Royal Adelaide Hospital Research Fund, The Hospital Research Fund 2020-2025, The Helmsley Trust 2020-2026.

Recent past GESA Board Member (ceased Sept 2023); CALHN employee (ongoing); Clinical Professor, University of Adelaide (ongoing)

Sally Antoniades

COI Declaration for ECCO 2025: None

Kristen Arnold

COI Declaration for ECCO 2025: None

Meghan Barnett

COI Declaration for ECCO 2025: None

Jakob Begun

COI Declaration for ECCO 2025: I have received honoraria or consulting fees from Abbvie, Janssen, Takeda, Pfizer, Ferring, Bristol Myers Squibb, Gilead, Tillott’s, Sandoz, Celltrion, Chiesi, Dr Falk, Microba, Glaxo Smith Klein, Antara, Suono, Therpeutic Guidelines, Research Review,

Grants: NHMRC, US Department of Defence, The Gutsy Foundation, The Gastroenterological Society of Australia, The University of Queensland, The Viertel Foundation, and The Mater Foundation

Laurel Brett

COI Declaration for ECCO 2025: None

Aura Cabaero

COI Declaration for ECCO 2025: None

Susan J Connor

COI Declaration for ECCO 2025: Ad Boards: Abbvie, Amgen, BMS, Celltrion, Eli Lilly, Ferring, GSK, Janssen, Organon, Pfizer, Takeda

Speaker Fees: Cornerstones Health, Dr Falk, Ferring, Janssen, Sandoz, Sydney IBD School, Takeda

Educational Support: DrFalk, Sandoz, Takeda

Research Support: Abbvie, Agency for Clinical Innovation, Amgen, BMS, Chiesi, Celltrion, DrFalk, Ferring, Janssen, Medical Research Future Fund, Pfizer, South Western Sydney Local Health District, Sydney Partnership for Health, Research and Enterprise, Takeda and The Leona M and Harry B Helmsley Charitable Trust

Chloe Davidson

COI Declaration for ECCO 2025: None

Shoma Dutt

COI Declaration for ECCO 2025: Advisory committee member and conference sponsorship: Dr Falk Pharma Australia Pty Ltd, Ferring Pharmaceuticals Pty Ltd

Advisory committee member: Abbvie

Angela Forbes

COI Declaration for ECCO 2025: None

Simon Ghaly

COI Declaration for ECCO 2025: Simon Ghaly has received speaker fees, research grants and travel grants from Dr. Falk pharma, Janssen, Pfizer, Abbvie, Sandoz, and Ferring and served on advisory boards for Pfizer and Abbvie.

Edward Giles

COI Declaration for ECCO 2025: Speaker Fees: Takeda, Janssen, Nutricia, Aspen Nutritionals, Abbvie, Evolution Health

Consultancy Fees: Abbvie, Janssen

Rachel Grafton

COI Declaration for ECCO 2025: None

Sabina Iliescu

COI Declaration for ECCO 2025: None

Andrew Kim

COI Declaration for ECCO 2025: None

Yoon-Kyo An

COI Declaration for ECCO 2025: Yoon-Kyo An has received consulting and speaker fees from AbbVie, Allimentiv, Bristol Myers Squibb, Eli Lilly, Dr Falk, Ferring, Glaxo-Smith Kline, Janssen, Pfizer, Samsung, Sandoz, Shire, and Takeda Pharmaceuticals; advisory board fees from AbbVie, Bristol Myers Squibb, Chiesi, Janssen, Microba, NPS Medicine Wise, the Council of Therapeutic Advisory Group (CATAG), Takeda Pharmaceuticals and Xencor; and research and educational support from AbbVie, Bristol Myers Squibb, Cannon, Celltrion, Chiesi, Dr Falk, Ferring, Janssen, Pfizer, Samsung, Sandoz, Siemen, and Takeda Pharmaceuticals.

Ian Lawrance

COI Declaration for ECCO 2025: None

Kate Lynch

COI Declaration for ECCO 2025: Kate Lynch has received speaker honoraria, advisory board fees, and/or conference

travel/registration support from AbbVie, Bristol-Myers Squibb (BMS), Chiesi, Dr. Falk,

Ferring, Gilead, Guidepoint, Intercept Pharmaceuticals, Janssen-Cilag, Merck Sharp &

Dohme (MSD), Norgine, Pfizer, Pliant, Sandoz, Takeda, and the Royal Adelaide Hospital

(RAH) Research Fund.

Jack McNamara

COI Declaration for ECCO 2025: None

Dominique Nano

COI Declaration for ECCO 2025: None

Watson Ng

COI Declaration for ECCO 2025: Educational and research funding from Jansen, Abbvie, Ferring, Takeda, Pfizer

Brigid Pinnuck

COI Declaration for ECCO 2025: Conference travel/registration from Gilead, MSD, Johnson & Johnson and Abbvie

Joseph Pipicilla

COI Declaration for ECCO 2025: Conference Sponsorship: Dr Falk Pharma Australia Pty Ltd, Ferring Pharmaceuticals Pty Ltd

CCCure Head of Operations & Company Secretary at the time of research and analysis

Consuelo Rivas

COI Declaration for ECCO 2025: None

Michael Schultz

COI Declaration for ECCO 2025: None

Crystal Seng

COI Declaration for ECCO 2025: None

Letisia Sin

COI Declaration for ECCO 2025: None

Heidi Su

COI Declaration for ECCO 2025: Advisory Board: Janssen, Takeda

Speaker Fees: Janssen, Takeda, Glaxo Smith Kline (GSK)

Gareth Walker

COI Declaration for ECCO 2025: G.W. has received speaker fees, educational support, advisory boards and research grants from Dr Falk Pharma, Janssen, Takeda, Ferring, Celltrion, Sandoz and Abbvie

Gabrielle Wark

COI Declaration for ECCO 2025: Conference travel/registration support from Dr Falk

Bill Wilson

COI Declaration for ECCO 2025: None

Our Research

Peer-Reviewed Publications

Upcoming Manuscripts

Accepted Abstracts

2025

FEBRUARY 202520th Congress of European Crohn's and Colitis Organisation (ECCO) - Berlin, Germany

2024

FEBRUARY 202419th Congress of European Crohn's and Colitis Organisation (ECCO) - Stockholm, Sweden

MAY 2024Digestive Disease Week (DDW) - Washington, USA

SEPTEMBER 2024Australian Gastroenterology Week (AGW) - Adelaide, Australia

2023

2022

2021

Conflict of Interest (COI) Declarations

FEBRUARY 2025
20th Congress of European Crohn's and Colitis Organisation (ECCO) - Berlin, Germany

FEBRUARY 2024
19th Congress of European Crohn's and Colitis Organisation (ECCO) - Stockholm, Sweden

MAY 2024
Digestive Disease Week (DDW) - Washington, USA

SEPTEMBER 2024
Australian Gastroenterology Week (AGW) - Adelaide, Australia